Johnson & Johnson (NYSE:JNJ) Trading Down 0.8%

Johnson & Johnson (NYSE:JNJ)’s share price was down 0.8% during mid-day trading on Wednesday . The company traded as low as $150.27 and last traded at $151.14. Approximately 1,157,067 shares changed hands during trading, a decline of 83% from the average daily volume of 6,989,932 shares. The stock had previously closed at $152.29.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on JNJ shares. Morgan Stanley cut their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 24th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Raymond James lifted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, March 13th. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $177.31.

Johnson & Johnson Trading Down 0.9 %

The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The firm has a market capitalization of $358.53 billion, a PE ratio of 10.77, a price-to-earnings-growth ratio of 2.52 and a beta of 0.53. The company has a fifty day moving average of $157.42 and a 200-day moving average of $156.08.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The firm had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same period in the prior year, the company posted $2.35 earnings per share. Johnson & Johnson’s revenue for the quarter was down 9.7% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. 4J Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 2.2% during the 4th quarter. 4J Wealth Management LLC now owns 2,835 shares of the company’s stock worth $444,000 after purchasing an additional 62 shares during the period. My Personal CFO LLC raised its holdings in Johnson & Johnson by 1.4% in the 4th quarter. My Personal CFO LLC now owns 4,550 shares of the company’s stock valued at $713,000 after acquiring an additional 62 shares in the last quarter. Eagle Strategies LLC lifted its position in shares of Johnson & Johnson by 1.8% in the 4th quarter. Eagle Strategies LLC now owns 3,589 shares of the company’s stock worth $563,000 after acquiring an additional 63 shares during the period. Clearview Wealth Advisors LLC increased its position in shares of Johnson & Johnson by 1.5% during the fourth quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock valued at $685,000 after purchasing an additional 64 shares during the period. Finally, Brookmont Capital Management raised its stake in shares of Johnson & Johnson by 0.4% in the fourth quarter. Brookmont Capital Management now owns 14,852 shares of the company’s stock valued at $2,328,000 after purchasing an additional 64 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.